In current clinical practice, the dynamic profile of m6A RNA modification, along with the expression levels of its regulatory proteins, shows promise as a prognostic biomarker and is directly linked to outcomes in various cancer types, e.g., elevated expression of YTHDF1 and IGF2BP2 correlates with worse overall survival (OS) in HCC [27]. Here, YTHDF1 is linked to hepatocellular carcinoma.